- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01425528
Study of Kuvan Treatment in Adults With GTPCH Deficiency
May 5, 2023 updated by: University of Utah
Pilot Study to Assess Impact of Kuvan® Supplementation as an Adjunct Treatment in Subjects With Dominantly-inherited GTPCH Deficiency on Mood, Behavioral and Motor Phenotypes
The purpose of this study is to identify the dose of Kuvan needed to normalize the levels of tetrahydrobiopterin (BH4) in patients with a Guanosine Triphosphate Cyclohydrolase (GTPCH) deficiency and to asses the potential impact of oral Kuvan on mood and function in individuals with GTPCH deficiency who may be experiencing symptoms of anxiety, depression, fatigue, trouble concentrating, or memory loss.
This will be a phase one study.
The investigators will monitor patients over a period of three to six months while on the medication.
Medication levels will be monitored by measuring the BH4 levels in cerebral spinal fluid (CSF).
Patients will undergo a baseline lumbar puncture and two follow-up lumbar punctures for this purpose.
The investigators will also monitor emotional function and motor function.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
12
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Utah
-
Salt Lake City, Utah, United States, 84132
- University of Utah
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- established diagnosis of GTPCH deficiency, supported by appropriate family history, CSF neurotransmitter studies, skin fibroblast enzyme assay and/or mutation analysis
- minimum age 18 years
- identified by self or others to have symptoms of anxiety, depression, fatigue, or other neurocognitive dysfunction (trouble concentrating, memory loss, etc)
- willingness to undergo at least 2 CSF evaluations for BH4 and neurotransmitter levels over an 8 to 12 week period
Exclusion Criteria:
- age < 18 years old
- unwillingness to undergo repeated CSF analysis
- lack of supporting diagnostic criteria
- concomitant medical problems or medications which would increase risk of Kuvan®
- concomitant psychiatric state, such as severe depression with suicidal ideation that requires immediate referral and alternative treatment intervention
- prior history of back surgery, abnormality or chronic pain that in the opinion of the investigator would increase risks associated with lumbar puncture
- significant obesity that might increase difficulty or risk in performing lumbar puncture
- if female, unwillingness to use birth control during the period of study drug administration
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Kuvan Cohort 1
This cohort will be enrolled first.
Analysis will be done to determine the optimum dosing of Kuvan to normalize BH4 levels in the Cerebral Spinal Fluid.
This cohort will begin at a dose of 20mg/kg/day.
|
Sapropterin will be taken daily for 12 or 24 weeks.
Starting dose will be 20mg/kg/day and will increase at the 8 week visit to 30 mg/kg/day.
Dosing may be further increased to as high as 40 mg/kg/day in attempt to normalize BH4 levels in CSF.
Starting dose for Cohort 2 will be determined from data analysis in Cohort 1.
Other Names:
|
Experimental: Kuvan Cohort 2
Participants in cohort 2 will be enrolled after the analysis of cohort 1 data has taken place.
Dosing for cohort 2 will be based on results obtained in cohort 1, but will plan on starting at 30 mg/kg/day.
|
Sapropterin will be taken daily for 12 or 24 weeks.
Starting dose will be 20mg/kg/day and will increase at the 8 week visit to 30 mg/kg/day.
Dosing may be further increased to as high as 40 mg/kg/day in attempt to normalize BH4 levels in CSF.
Starting dose for Cohort 2 will be determined from data analysis in Cohort 1.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in BH4 Levels in Cerebral Spinal Fluid
Time Frame: Baseline, 8 wks, 12 wks
|
Identify dosing range of oral Kuvan® necessary and sufficient to normalize CSF BH4 levels in adults with GTPCH Deficiency.
|
Baseline, 8 wks, 12 wks
|
Change in Neurotransmitter Metabolite Levels in Cerebral Spinal Fluid
Time Frame: Baseline, 8 wks, 12 wks
|
Baseline, 8 wks, 12 wks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hamilton Anxiety Rating Scale
Time Frame: Baseline, 8 wks, 12 wks, 24 wks (optional)
|
The Hamilton Anxiety Scale (HAS or HAMA) is a 14-item test measuring the severity of anxiety symptoms.Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe.
|
Baseline, 8 wks, 12 wks, 24 wks (optional)
|
Behavior Rating Inventory of Executive Function (BRIEF-A) Adult Version
Time Frame: Baseline, 8 wks, 12 wks, 24 wks (optional)
|
The Behavior Rating Inventory of Executive Function-Adults (BRIEF-A) is a 75-item scale designed to assess self-reported behaviors associated with executive function.
Answers are scored from 1, never a problem, to 7, always a problem.
Higher scores indicate poor executive function.
|
Baseline, 8 wks, 12 wks, 24 wks (optional)
|
Beck Depression Inventory
Time Frame: Baseline, 8 wks, 12 wks, 24 wks (optional)
|
The Beck Depression Inventory (BDI) is a 21-item, self-rated scale that evaluates key symptoms of depression including mood, pessimism, sense of failure, self-dissatisfaction, guilt, punishment, self-dislike, self-accusation, suicidal ideas, crying, irritability, social withdrawal, indecisiveness, body image change, work difficulty, insomnia, fatigability, loss of appetite, weight loss, somatic preoccupation, and loss of libido.
The 21 symptoms and attitudes contained in the BDI reflect the intensity of the depression; items receive a rating of zero to three to reflect their intensity and are summed linearly to create a score which ranges from 0 to 63. Scores from 0 through 9 indicate no or minimal depression; scores from 10 through 18 indicate mild to moderate depression; scores from 19 through 29 indicate moderate to severe depression; and scores from 30 through 63 indicate severe depression.
|
Baseline, 8 wks, 12 wks, 24 wks (optional)
|
Brief Symptom Inventory
Time Frame: Baseline, 8 wks, 12 wks, 24 wks (optional)
|
The Brief Symptom Inventory (BSI) consists of 53 items covering nine symptom dimensions: Somatization, Obsession-Compulsion, Interpersonal Sensitivity, Depression, Anxiety, Hostility, Phobic anxiety, Paranoid ideation and Psychoticism; and three global indices of distress: Global Severity Index, Positive Symptom Distress Index, and Positive Symptom Total.
The global indices measure current or past level of symptomatology, intensity of symptoms, and number of reported symptoms, respectively.
Each item of the BSI is rated on a 5-point scale of distress (0-4), ranging from "not at all" (0) at one pole to "extremely" (4) at the other.
|
Baseline, 8 wks, 12 wks, 24 wks (optional)
|
Pittsburgh Sleep Quality Index
Time Frame: Baseline, 8 wks, 12 wks, 24 wks (optional)
|
The Pittsburgh Sleep Quality Index (PSQI) The 19 self-rated items are combined to form seven "component" scores, each of which has a range of 0-3 points.
In all cases, a score of "0" indicates no difficulty, while a score of "3" indicates severe difficulty.
The component scores are then added to yield one "global" score, with a range of 0-21 points, "0" indicating no difficulty and "21" indicating severe difficulties in all areas
|
Baseline, 8 wks, 12 wks, 24 wks (optional)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Kathryn J Swoboda, MD, University of Utah
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2011
Primary Completion (Actual)
August 1, 2013
Study Completion (Actual)
August 1, 2013
Study Registration Dates
First Submitted
August 25, 2011
First Submitted That Met QC Criteria
August 26, 2011
First Posted (Estimated)
August 30, 2011
Study Record Updates
Last Update Posted (Actual)
June 2, 2023
Last Update Submitted That Met QC Criteria
May 5, 2023
Last Verified
March 1, 2014
More Information
Terms related to this study
Other Study ID Numbers
- 48052
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on GTP Cyclohydrolase Deficiency
-
Washington University School of MedicineUniversity of California, Davis; Universidad San Francisco de Quito; Pan American...CompletedCholine Deficiency | Vitamin B-12 Deficiency | Lipids Deficiency | Amino Acids DeficiencyEcuador
-
Nutrition Institute, SloveniaEuropean Regional Development Fund; Vizera d.o.o.; Frutarom Etol d.o.o.CompletedVitamin B 12 Deficiency | Vitamin d Deficiency | Protein DeficiencySlovenia
-
Texas A&M UniversityUnknownCognitive Change | Nutritional Anemia | Diet, Healthy | Nutrient Deficiency | Diet; Deficiency | Visual Spatial Processing | Dietary Deficiency | Dietary B12 Deficiency | Dietary Zinc Deficiency | Dietary Vitamin B12 Deficiency Anemia | Dietary Deficiency of Selenium and Vitamin EUnited States
-
SourseCitruslabsActive, not recruitingMood | Energy Supply; Deficiency | B12 Deficiency VitaminUnited States
-
University of California, DavisUniversity of California, San Francisco; University of Rhode Island; Ethiopian... and other collaboratorsEnrolling by invitationVitamin B 12 Deficiency | Folate Deficiency | Iodine Deficiency | Anemia Deficiency | Salt Intake | Anemia MacrocyticEthiopia
-
ProofPilotJoovvUnknownTestosterone Deficiency | Estrogen DeficiencyUnited States
-
Meir Medical CenterCompletedFolic Acid Deficiency | Vitamin B12 DeficiencyIsrael
-
University Medical Centre LjubljanaCompletedBody Weight | IVF | Nutrient Deficiency | Dietary Vitamin B12 Deficiency Anemia | Dietary Folate Deficiency AnemiaSlovenia
-
Nutrition Institute, SloveniaNational Institute of Public Health, Slovenia; University Medical Centre LjubljanaCompletedThyroid Diseases | Iron-deficiency | Vitamin D Deficiency | Nutritional Status | Vitamin B 12 Deficiency | Folic Acid Deficiency | Diet | Nutrient Deficiency | Micronutrient DeficiencySlovenia
-
Quadram Institute BioscienceNorfolk and Norwich University Hospitals NHS Foundation TrustEnrolling by invitationIron Deficiency (Without Anemia) | B12 Deficiency VitaminUnited Kingdom
Clinical Trials on Sapropterin
-
University of California, San DiegoBioMarin PharmaceuticalWithdrawnBehavioral Manifestations of Lesch-Nyhan DiseaseUnited States
-
Washington University School of MedicineUniversity of Missouri-Columbia; Northwestern University; Oregon Health and Science... and other collaboratorsTerminated
-
BioMarin PharmaceuticalTerminatedPhenylketonuriaItaly, Switzerland
-
University of Missouri-ColumbiaBioMarin PharmaceuticalCompletedPhenylketonuriaUnited States
-
The University of Texas Health Science Center,...BioMarin PharmaceuticalTerminatedPhenylketonuria | HyperphenylalaninemiaUnited States
-
Universidade do PortoBioMarin Pharmaceutical; Centro Hospitalar do PortoCompleted
-
Providence VA Medical CenterBioMarin Pharmaceutical; LifespanCompletedHeart Failure | Cardiovascular DiseaseUnited States
-
Washington University School of MedicineUniversity of Missouri-Columbia; BioMarin PharmaceuticalCompleted
-
The Children's Health CouncilBioMarin PharmaceuticalCompleted
-
Fundacion Clinic per a la Recerca BiomédicaCompletedLiver Cirrhosis | Portal HypertensionSpain